Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of U.S. dollars ($)	Three Months Ended March 31, 2021
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	225	$	225	$	—
License Fee – Over time	58		—		58
Total Drug Products	283		225		58
Concentrate Products
Product Sales – Point-in-time	14,705		13,201		1,504
License Fee – Over time	485		485		—
Total Concentrate Products	15,190		13,686		1,504
Net Revenue	$	15,473	$	13,911	$	1,562

In thousands of U.S. dollars ($)	Three Months Ended March 31, 2020
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	199	$	199	$	—
License Fee – Over time	56		—		56
Total Drug Products	255		199		56
Concentrate Products
Product Sales – Point-in-time	15,112		13,506		1,606
License Fee – Over time	490		490		—
Total Concentrate Products	15,602		13,996		1,606
Net Revenue	$	15,857	$	14,195	$	1,662

Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands of U.S. dollars ($)	March 31, 2021		December 31, 2020
Receivables, which are included in "Trade and other receivables"	$	6,597	$	4,171
Contract liabilities	$	9,646	$	10,190